Showing 4651-4660 of 7638 results for "".
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite trea…
- Brickell Biotech Announces Funding for Development of Novel Dermatology Treatmentshttps://practicaldermatology.com/news/20130226-brickell_biotech_announces_funding_for_development_of_novel_dermatology_treatments/2459608/Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatit…
- CeraVe Launches Seven New Sunscreens with Barrier-Repairing Ceramideshttps://practicaldermatology.com/news/20130225-cerave_launches_seven_new_sunscreens_with_barrier-repairing_ceramides/2459609/Seven newCeraVe sunscreening products are now available in the Sun Protection aisle at drugstores and mass market retailers nationwide. The CeraVe Sun Care line, developed with dermatologists, includes products for the face and body with various applications offering both broad spectrum SPF 30 and …
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90…
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated th…
- FotoFinder Universe App Permits Image Access Via iPadhttps://practicaldermatology.com/news/20130215-fotofinder_universe_app_permits_image_access_via_ipad/2459614/Physicians can access before and after photos from an iPad for viewing, editing, and comparison, using FotoFinder's new Universe app for iPad 2, 3 and 4 and iPad mini. Used in conjunction with the company's mediscope photo documentation suite and Satellite communication interface technology, the U…
- Aqua Pharmaceuticals Announces New VP of Saleshttps://practicaldermatology.com/news/20130212-aqua_pharmaceuticals_announces_new_vp_of_sales/2459617/Aqua Pharmaceuticals recently promoted Ted White to Chief Operating Officer (COO). White moves to the new role from his previous position as Vice President of Sales. As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in…
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now ava…
- Survey Data Highlight Expenses and Access-to-Care for Psoriasis Patientshttps://practicaldermatology.com/news/20130208-survey_data_highlight_expenses_and_access-to-care_for_psoriasis_patients/2459618/New findings from the National Psoriasis Foundation (NPF) indicate that patients with psoriasis and psoriatic arthritis patients spend more than $2,500 per year in out-of-pocket costs for their disease. In an analysis of eight years of data to determine access-to-care issues and out-of-pocket costs…
- Obagi and Suneva Partner to Distribute Facial Rejuvenation Complexhttps://practicaldermatology.com/news/20130201-obagi_and_suneva_parter_to_distribute_facial_rejuvenation_complex/2459622/Obagi Medical Products and Suneva Medical jointly announced a partnership to co-distribute ReGenica Facial Rejuvenation Complex, a product that accelerates the appearance of post-laser skin through the fusion of stem cells and growth factors. It contains the Multipotent CCM Complex (Cell Conditione…